Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $8.24 Consensus Price Target from Brokerages
Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) have earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year […]
Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) have earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year […]
